Cortexyme announces leadership appointments to support advancement of atuzaginstat and pipeline expansion

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a company advancing a pivotal trial in alzheimer's disease on schedule to be announced in q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments to support the continued advancement and commercial planning of atuzaginstat, as well as the company's pipeline expansion and regulatory affairs capabilities. “expanding cortexyme's leadership team strengthens our
QNCX Ratings Summary
QNCX Quant Ranking